COMMUNIQUÉS West-GlobeNewswire

Building Muscle After 50: Why CrazyBulk Muscle Growth & Strength Supplements for Over 50's are Best Sellers in 2025
13/08/2025
New York City, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- In 2025, CrazyBulk is redefining building muscle after 50 by boosting healthy testosterone levels, improving mTOR responsiveness, and enhancing recovery - so men 50+ [...]
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
13/08/2025
Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating [...]
Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results
13/08/2025
Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates more than 1.5 [...]
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
13/08/2025
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today [...]
Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
13/08/2025
Completed Strategic Leadership and Operational Transformation from R&D to Commercial Operations Rebranded as Dyadic Applied BioSolutions to Reflect Our New Operational Priorities Full Redesign of Corporate Website [...]
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
13/08/2025
Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately [...]
Glass House Brands Reports Second Quarter 2025 Financial Results
13/08/2025
Results surpassed expectations across key metrics including biomass production, revenue, gross profit, and Adjusted EBITDA Wholesale biomass production was 230,748 pounds, up 54% year-over-year Cost of production was $ [...]
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for [...]
STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
13/08/2025
HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
13/08/2025
GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic [...]
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
13/08/2025
- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS [...]
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
13/08/2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard [...]
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
13/08/2025
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today [...]
Codexis Reports Second Quarter 2025 Financial Results
13/08/2025
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM [...]
SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
13/08/2025
Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI [...]
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
13/08/2025
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or [...]
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL [...]
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
13/08/2025
Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line [...]
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of [...]

Pages